
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.**

Date of Report: December 31, 2007
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission File Number)

59-3410522
(IRS Employer
Identification Number)

13700 Progress Blvd., Alachua, FL
(Address of principal executive offices)

32615
(Zip Code)

386-418-4018
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On December 31, 2007, Dr. Robert Zahradnik resigned as Chief Executive Officer, President and a director of the Company as a result of his retirement.

Effective December 31, 2007, Dr. Ronald P. Evens, a Director, has been named President and Chief Executive Officer of the Company replacing Dr. Zahradnik. Dr. Evens will also continue to serve on the Company's Board of Directors. Dr. Evens has served as Director since June 15, 2007. He is also President and CEO of MAPS 4 Biotech, a biotechnology consulting company in Jacksonville, Florida, and is Clinical Professor, University of Florida, College of Pharmacy. Prior to that, Dr. Evens has had a distinguished industrial career, including thirteen years at Amgen, a leading human therapeutics biotechnology company, where he served as Senior Director and Head of Professional Services. Prior to that, he spent six years at Bristol-Myers, a global pharmaceutical company, where he was Associate Director, Clinical Research & Medical Services. He has written/edited the book, "Drug & Biological Development, From Molecule to Product & Beyond" (Springer, 2007), and has served on twelve professional and medical Boards of Directors or Advisory Boards.

Dr. Evens employment is "at will" and may be terminated by him or the Company upon 30 days written notice. The expected tenure of his employment is until a permanent chief executive officer is successfully recruited and retained in 2008. The Company has agreed to a compensation arrangement with Dr. Evens and the material terms include monthly compensation of \$14,583.33 or an annual salary of \$175,000.00. Additionally, Dr. Evens will be awarded 30,000 stock options at an exercise price of \$0.44 which will vest at the time of hiring a permanent chief executive officer.

Concurrently with the above, the Company also announced the appointment of Richard T. Welch, as an independent director to the Board of Directors to fill the vacancy left by Dr. Zahradnik. Rick Welch is President of Welch Business Solutions and Consulting, LLC in Tampa, Florida, and has served as a Director and CFO for several healthcare companies, including Orthopedic Development Corporation, Albiorex, LLC, Medi-Spa's of America, Inc., and Vision Twenty-One. Previously, he served as executive vice-president of finance and administration, and earlier as CFO, for Sports and Recreation, Inc. Rick is also a CPA and received his BS in management and accounting from Louisiana State University. In connection with his appointment, Mr. Welch was awarded 65,000 stock options at an exercise price of \$0.44 which vests immediately.

Mr. Welch will be expected to serve on the Company's audit committee to replace Dr. Evens on such committee as a result of Dr. Evens no longer qualifying as an independent director.

On January 3, 2008, Derek Hennecke was appointed to serve on the Board of Directors as an independent director bringing the Board to four directors of which two members are independent directors. Derek is President and CEO of Xcelience, a pharmaceutical formulation development and contract manufacturing company headquartered in Tampa, FL. Prior to this, he was VP and GM of Pharmaceuticals and Biopharmaceuticals of MDS Pharma Sciences and was responsible for the business and operations of CRO formulation development. Before joining MDS, he held various drug development management positions in Canada, Egypt, The Netherlands and Mexico. In connection with his appointment, Mr. Hennecke was awarded 65,000 stock options at an exercise price of \$0.41 which will vest immediately. Mr. Hennecke will be expected to serve on the audit committee.

A copy of the January 2, 2008 press release announcing the retirement of Dr. Zahradnik and the appointment of Dr. Evens as chief executive officer and president and the appointment of Richard Welch as a director is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release of Orogenics, Inc. dated January 2, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 02, 2008

ORAGENICS, INC

By: /s/ Dorothy Delfino

Dorothy Delfino

CFO

EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Orogenics, Inc dated January 02, 2008

Orogenics announces retirement of its CEO, selects a new CEO and President, and appoints a new Board Member.

Alachua, FL (January 2, 2008) – Orogenics, Inc. (AMEX:ONI), a biotechnology development company, announced today several new developments in the leadership and direction of the company, intended collectively to begin re-positioning the company and advance its products and technologies.

Company Management: Dr. Robert Zahradnik, the CEO, President, and Board member for the past 2 years, has decided to retire from Orogenics effective December 31, 2007, so he can enjoy more time with his family. He will continue to support Orogenics in a part-time role as a consultant focusing on out-licensing. David J. Gury, Chairman of the Board announced that Dr. Ronald P. Evens, currently a Director, has accepted the positions of CEO and President. The Board of Directors thanks Bob Zahradnik, who also was a founding member of Orogenics, for his invaluable service to Orogenics. Further, Mr. Gury states, “Ron Evens, our new CEO, brings over 25 years of substantial management and biopharma industry experience into his new leadership role, at a time when those particular knowledge and skills, as well as his personal drive, will help Orogenics reposition the company and bring its products and technologies to their full potential.” Dr. Jeff Hillman, Dotti Delfino, and David Gury remain the CSO, CFO, and Chairman, respectively.

Board of Directors: Orogenics announced the appointment of a new Director, Richard T. Welch. Rick is President of Welch Business Solutions and Consulting, LLC in Tampa, Florida, and has served as a Director and CFO for several healthcare companies, including Orthopedic Development Corporation, Albiorex, LLC, Medi-Spa’s of America, Inc, and Vision Twenty-One. Previously, he served as executive vice-president of finance and administration, and earlier as CFO, for Sports and Recreation, Inc. Rick is also a CPA and received his BSc in management and accounting from Louisiana State University. Ronald Evens, CEO and President, states, “Rick Welch, as an independent Director will add significant strength and breadth to our Board with his business and financial acumen”. Additional members to the Board are planned in the future.

About Orogenics: Orogenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Orogenics’ current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual

results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Ronald P. Evens, 386-418-4018 X222
www.oragenics.com